Salk Institute

Technologies Available for Licensing

Modular Assembly Retroviral Vectors and Uses Therefor

Inventors: Fred H. Gage and Steven T. Suhr
Potential Uses: Gene Expression/Gene Therapy
Gene transfer vectors with the capacity for prolonged or modulated transgene expression

This invention relates to novel retroviral vectors containing modified long terminal repeats (LTR) which enable high level and ligand-modulatable expression of a desired gene product, even after prolonged periods of cellular quiescence. These novel vectors overcome proviral transcriptional inactivation which occurs in cultured primary cells that are growth arrested due to environmental constraints such as contact inhibition and/or nutrient starvation. These vectors represent a class of retroviral vectors in which LTR-promoted proviral expression in infected cells may be maintained or increased, even in situations generally considered to be non-permissive for retroviral vectors. This invention can be applied: as gene transfer vectors with the capacity for prolonged or modulated transgene expression for either in vivo or ex vivo gene therapy; as gene transfer vectors for efficient production of transgenic animals; as vectors for efficient gene transfer to developing embryos; and as vectors with inducible high titers.

Salk No: S96013
Patent Status: U.S. Patent No. 5,919,667 issued July 6, 1999
Publications: No publications to date
License Terms: Nonexclusive field of use licenses negotiable
Contact: Robert MacWright, Ph.D., Esq., Director, OTD, 858.453.4100 x1703, rmacwright@salk.edu

Get Involved
Join our online community
Facebook    Facebook
Twitter    Twitter
YouTube    YouTube
RSS    RSS
Contact
Salk Institute for Biological Studies
Street: 10010 North Torrey Pines Rd
City: La Jolla, CA 92037
Email: webrequest@salk.edu
Phone: 858.453.4100
Charity Navigator Rating
© Copyright 2013 Salk Institute for Biological Studies About Scientists & Research News & Media Events Support